The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a period of shifting healthcare dynamics, analyst revisions serve as a key signal for capital flows into pharmaceutical distribution stocks. Barclays maintained its Overweight rating on McKesson (MCK) but lowered its price target to $925 from $1,050. The bank cited increased conservatism regarding market visibility for the cut, despite expressing continued confidence in the company's long-term business model.
This adjustment follows significant corporate activity, including a recent $1.25 billion investment from Apollo Funds aimed at strengthening McKesson's strategic position. Compared to peers, Cardinal Health (CAH) trades at similar valuation multiples, while market data shows investors are weighing these targets against consistent growth in specialty pharmacy segments. Analyst views remain divided on the FY27 outlook, with UBS maintaining a more cautious stance relative to Barclays' optimism.
Sign in to access this content
Sign InMcKesson shares closed at $784.05 on June 12, 2026, after trading within a range of $782.47 to $796.54. Investors should watch for upcoming U.S. retail sales data in the economic calendar for indirect sector impact. Additionally, any further guidance regarding the deployment of the Apollo Funds investment will be a primary catalyst for the stock to test resistance levels near the $800 mark.